Relmada Therapeutics, Inc. (RLMD)
NASDAQ: RLMD · Real-Time Price · USD
7.24
+0.21 (2.99%)
At close: Apr 28, 2026, 4:00 PM EDT
7.24
0.00 (0.00%)
After-hours: Apr 28, 2026, 4:11 PM EDT
Relmada Therapeutics Income Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
| FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
| Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
| Selling, General & Admin | 32.22 | 37.72 | 48.89 | 47.93 | 35.08 | |
| Research & Development | 23.98 | 46.18 | 54.81 | 113.32 | 90.62 | |
| Operating Expenses | 56.2 | 83.89 | 103.7 | 161.25 | 125.7 | |
| Operating Income | -56.2 | -83.89 | -103.7 | -161.25 | -125.7 | |
| Interest & Investment Income | 1.4 | 3.53 | 5.15 | 2.66 | 1.2 | |
| EBT Excluding Unusual Items | -54.8 | -80.36 | -98.55 | -158.59 | -124.5 | |
| Merger & Restructuring Charges | -2.9 | - | - | - | - | |
| Gain (Loss) on Sale of Investments | 0.32 | 0.38 | -0.24 | -4.81 | -1.25 | |
| Other Unusual Items | - | - | - | 6.35 | - | |
| Pretax Income | -57.39 | -79.98 | -98.79 | -157.04 | -125.75 | |
| Net Income | -57.39 | -79.98 | -98.79 | -157.04 | -125.75 | |
| Net Income to Common | -57.39 | -79.98 | -98.79 | -157.04 | -125.75 | |
| Shares Outstanding (Basic) | 39 | 30 | 30 | 30 | 18 | |
| Shares Outstanding (Diluted) | 39 | 30 | 30 | 30 | 18 | |
| Shares Change (YoY) | 30.89% | 0.21% | 1.59% | 68.80% | 12.56% | |
| EPS (Basic) | -1.45 | -2.65 | -3.28 | -5.30 | -7.16 | |
| EPS (Diluted) | -1.45 | -2.65 | -3.28 | -5.30 | -7.16 | |
| Free Cash Flow | -45.79 | -51.76 | -51.66 | -103.8 | -91.87 | |
| Free Cash Flow Per Share | -1.16 | -1.72 | -1.72 | -3.50 | -5.23 | |
| EBITDA | - | - | - | -161.25 | -125.7 | |
| D&A For EBITDA | - | - | - | 0 | 0 | |
| EBIT | -56.2 | -83.89 | -103.7 | -161.25 | -125.7 | |
Source: S&P Capital IQ. Standard template.
Financial Sources.